Search results for "Convulsants"

showing 10 items of 125 documents

Dose-Related Concentrations of Neuroactive/Psychoactive Drugs Expected in Blood of Children and Adolescents

2020

PURPOSE Therapeutic drug monitoring is highly recommended for children and adolescents treated with neurotropic/psychotropic drugs. For interpretation of therapeutic drug monitoring results, drug concentrations (C/D) expected in a "normal" population are helpful to identify pharmacokinetic abnormalities or nonadherence. Using dose-related concentration (DRC) factors obtained from pharmacokinetic data, C/D ranges expected under steady state can be easily calculated by multiplication of DRC by the daily dose. DRC factors, however, are defined only for adults so far. Therefore, it was the aim of this study to estimate DRC factors for children and adolescents and compare them with those of adul…

MaleDrugTopiramatePediatricsmedicine.medical_specialtyAdolescentmedicine.medical_treatmentmedia_common.quotation_subjectPopulation030226 pharmacology & pharmacy03 medical and health sciences0302 clinical medicinePharmacokineticsparasitic diseasesHumansMedicinePharmacology (medical)ChildeducationAntipsychoticOxcarbazepinemedia_commonPharmacologyeducation.field_of_studyDose-Response Relationship Drugmedicine.diagnostic_testbusiness.industryAge FactorsArea under the curveAntidepressive AgentsTherapeutic drug monitoringArea Under CurveAnticonvulsantsCentral Nervous System StimulantsFemaleDrug MonitoringbusinessAntipsychotic AgentsHalf-Lifemedicine.drugTherapeutic Drug Monitoring
researchProduct

Epidemiology and diagnostic and therapeutic management of febrile seizures in the Italian pediatric emergency departments: A prospective observationa…

2015

AIM: Febrile seizures (FS) involve 2-5% of the paediatric population, among which Complex FS (CFS) account for one third of accesses for FS in Emergency Departments (EDs). The aim of our study was to define the epidemiology, the clinical, diagnostic and therapeutic approach to FS and CFSs in the Italian EDs. METHODS: A multicenter prospective observational study was performed between April 2014 and March 2015. Patients between 1 and 60 months of age, randomly accessing to ED for ongoing FS or reported FS at home were included. Demographic features and diagnostic-therapeutic follow-up were recorded. FS were categorized in simple (<10min), prolonged (10-30min) and status epilepticus (>3…

MaleEmergency Medical ServicesPediatricsNeurologyFebrileEpilepsyStatus Epilepticus0302 clinical medicineBolus (medicine)EpidemiologyPrevalenceItalian populationEpidemiologic studyProspective StudiesChildPediatricEmergency ServiceAge FactorsSettore MED/38Emergency department; Epidemiologic study; Italian population; Pediatrics; Simple and complex febrile seizures;ItalyNeurologyChild PreschoolPopulation studyAnticonvulsantsFemaleEmergency Service HospitalEmergency department; Epidemiologic study; Italian population; Pediatrics; Simple and complex febrile seizures; Age Factors; Anticonvulsants; Child Preschool; Emergency Medical Services; Emergency Service Hospital; Female; Follow-Up Studies; Humans; Infant; Italy; Male; Prevalence; Prospective Studies; Seizures Febrile; Status Epilepticusmedicine.drugmedicine.medical_specialtypediatricsSeizures FebrileNOHospital03 medical and health sciencesSeizures030225 pediatricsmedicineHumansPreschoolEmergency departmentbusiness.industrySimple and complex febrile seizuresInfantEmergency departmentmedicine.diseaseemergency department; epidemiologic study; italian population; pediatrics; simple and complex febrile seizures; neurology; neurology (clinical)MidazolamObservational studyNeurology (clinical)business030217 neurology & neurosurgeryFollow-Up StudiesEpilepsy Research
researchProduct

Anticonvulsant and antidepressant activity of the selected terpene GABA derivatives in experimental tests in mice

2006

The present study was designed to investigate the central nervous system activity of terpene GABA (and piracetam) derivatives designated as BF-1, BF-2, BF-3, BF-4, BF-5, BF-6. We assessed their anticonvulsant activity in the two main mouse models of seizures (MES-test, PTZ-test), an antidepressant-like effect in the forced swim test (FST), as well as an influence on spontaneous locomotor activity. Our study demonstrated the strong anticonvulsant activity of (1S,3R,7R)-(-)-3,8,8-trimethyl-4-aza-bicyclo[5.1.0]acetate-5-one hydrochloride (compound BF-2) in the PTZ-test. Activity of BF-2 was equipotent to ethosuximide (380 mg/kg, po) in the PTZ-test, when used at a dose of 100 mg/kg, po. No neu…

MaleGABAantidepressant-like activitymiceReceptors GABA-BAnimalsAnticonvulsantsMotor Activityanticonvulsant-Antidepressive AgentsSwimminggamma-Aminobutyric AcidterpenesPharmacological Reports
researchProduct

Anticonvulsants do not suppress long-term potentiation (LTP) in the rat hippocampus

1991

Long-term potentiation (LTP) of population spikes in the CA1 area of rat hippocampus was induced by tetanic stimulation of stratum radiatum in slices kept submerged in a perfusion chamber. Addition of the two antiepileptic drugs phenytoin or the diazepine midazolam to the medium did not significantly alter this phenomenon within 22 min after the tetanus. The early enhancement (post-tetanic potentiation, PTP) was reduced only by phenytoin. Therefore an interaction of these drugs with N-methyl-D-aspartate (NMDA) receptors and LTP induction is unlikely.

MaleMidazolammedicine.medical_treatmentPopulationHippocampusIn Vitro TechniquesPharmacologyNeurotransmissionHippocampusLTP inductionmedicineAnimalseducationEvoked Potentialsgamma-Aminobutyric Acideducation.field_of_studyChemistryGeneral NeuroscienceRats Inbred StrainsLong-term potentiationRatsAnticonvulsantnervous systemPhenytoinSynapsesNMDA receptorAnticonvulsantsFemaleTetanic stimulationNeuroscience Letters
researchProduct

Synthesis, resolution, stereochemistry, and molecular modeling of (R)- and (S)-2-acetyl-1-(4’-chlorophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinol…

2007

Abstract Recently we identified ( R , S )-2-acetyl-1-(4′-chlorophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline ( 6 ) as a potent non-competitive AMPA receptor antagonist able to prevent epileptic seizures. We report here the optimized synthesis of compound 6 , its resolution by chiral preparative HPLC, and the absolute configuration of ( R )-enantiomer established by X-ray diffractometry. The biological tests of the single enantiomers revealed that higher anticonvulsant and antagonistic effects reside in ( R )-enantiomer as also suggested by molecular modeling studies.

MaleModels MolecularMolecular modelStereochemistryClinical BiochemistryPharmaceutical ScienceConvulsantsAMPA receptorCrystallography X-RayBiochemistryChemical synthesisMicrowave-assisted synthesisEnantiomeric resolutionchemistry.chemical_compoundMiceSeizuresTetrahydroisoquinolinesTetrahydroisoquinolineDrug DiscoveryAnticonvulsantAnimalsMolecular BiologyMolecular StructureTetrahydroisoquinolineOrganic ChemistryAntagonistAbsolute configurationTetrahydroisoquinoline; Microwave-assisted synthesis; Enantiomeric resolution; AnticonvulsantBiological activityStereoisomerismRatschemistryReceptors GlutamateMolecular MedicineEnantiomerExcitatory Amino Acid Antagonists
researchProduct

Modulatory effects of nitric oxide-active drugs on the anticonvulsant activity of lamotrigine in an experimental model of partial complex epilepsy in…

2007

Abstract Background The effects induced by administering the anticonvulsant lamotrigine, the preferential inhibitor of neuronal nitric oxide synthase 7-nitroindazole and the precursor of NO synthesis L-arginine, alone or in combination, on an experimental model of partial complex seizures (maximal dentate gyrus activation) were studied in urethane anaesthetized rats. The epileptic activity of the dentate gyrus was obtained through the repetitive stimulation of the angular bundle and maximal dentate gyrus activation latency, duration and post-stimulus afterdischarge duration were evaluated. Results Either Lamotrigine (10 mg kg-1) or 7-nitroindazole (75 mg kg-1) i.p. administration had an ant…

MalePARTIAL COMPLEX EPILEPSYIndazolesArgininemedicine.medical_treatmentLamotriginePharmacologyArginineLamotrigineNitric OxideSettore BIO/09 - Fisiologialcsh:RC321-571Nitric oxideCellular and Molecular Neurosciencechemistry.chemical_compoundEpilepsy Complex PartialmedicineAnimalsDrug InteractionsEnzyme InhibitorsRats Wistarlcsh:Neurosciences. Biological psychiatry. NeuropsychiatryNitric oxide Lamotrigine epilepsy controlbiologyTriazinesExperimental modelGeneral NeuroscienceDentate gyruslcsh:QP351-495BrainElectric StimulationRatsNitric oxide synthaseDisease Models Animallcsh:Neurophysiology and neuropsychologyAnticonvulsantnervous systemchemistryDentate Gyrusbiology.proteinAnticonvulsantsNitric Oxide SynthaseResearch Articlemedicine.drugBMC Neuroscience
researchProduct

Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience

2010

This is the first multicenter Italian experience with rufinamide as an adjunctive drug in children, adolescents and adults with Lennox-Gastaut syndrome. The patients were enrolled in a prospective, add-on, open-label treatment study from 11 Italian centers for children and adolescent epilepsy care. Forty-three patients (26 males, 17 females), aged between 4 and 34 years (mean 15.9 ± 7.3, median 15.0), were treated with rufinamide for a mean period of 12.3 months (range 3-21 months). Twenty patients were diagnosed as cryptogenic and 23 as symptomatic. Rufinamide was added to the baseline therapy at the starting dose of 10mg/kg body weight, evenly divided in two daily doses and then increased…

MalePediatricsLennox-Gastaut syndromeAtypical absence seizuresRufinamideLennox–Gastaut syndrome; Rufinamide; Orphan drug; Pediatrics; Epilepsy; Drop attacksInfantilePediatricsSpasmsEpilepsyRufinamideDrop attacks; Epilepsy; Lennox-Gastaut syndrome; Orphan drug; Pediatrics; Rufinamide; Adolescent; Adult; Anticonvulsants; Child; Child Preschool; Drug Therapy Combination; Female; Humans; Intellectual Disability; Italy; Lennox Gastaut Syndrome; Male; Spasms Infantile; Treatment Outcome; Triazoles; Valproic Acid; Young Adult; Neurology (clinical); NeurologyChildPediatricValproic AcidDrop attacksGeneral MedicineSettore MED/39 - Neuropsichiatria InfantileTreatment OutcomeItalyNeurologyAnesthesiaChild PreschoolCombinationVomitingAnticonvulsantsDrug Therapy CombinationFemalemedicine.symptomSpasms Infantilemedicine.drugAdultmedicine.medical_specialtyAdolescentClinical NeurologyIrritabilityYoung AdultDrug TherapyIntellectual DisabilitymedicineHumanspediatrics epilepsyPreschoolAdverse effectLennox–Gastaut syndrome; rufinamide; orphan drug; pediatrics epilepsy; drop attacks; refractory epilepsy.EpilepsyOrphan drugbusiness.industryLennox Gastaut SyndromeValproic Acidrefractory epilepsyTriazolesmedicine.diseaseNeurology (clinical)businessLennox–Gastaut syndromeLennox–Gastaut syndrome
researchProduct

Survey on treatments for primary headaches in 13 specialized juvenile Headache Centers: The first multicenter Italian study

2017

Abstract Aim The purpose of this retrospective multicenter study was to evaluate the use and the self-perceived efficacy and tolerability of pharmacological and non-pharmacological treatments in children and adolescents with primary headaches. Methods Study of a cohort of children and adolescents diagnosed with primary headache, consecutively referred to 13 juvenile Italian Headache Centers. An ad hoc questionnaire was used for clinical data collection. Results Among 706 patients with primary headaches included in the study, 637 cases with a single type of headache (migraine 76% – with and without aura in 10% and 67% respectively; tension-type headache 24%) were selected (mean age at clinic…

MalePediatricsmedicine.medical_specialtyAdolescentMigraine DisordersAdolescents; Children; Migraine; Primary headaches; Tension-type headache; Treatment; Pediatrics Perinatology and Child Health; Neurology (clinical)Tension-typeTriptansPizotifenPediatrics03 medical and health sciences0302 clinical medicinechildrenPrimary headacheBehavior TherapySurveys and QuestionnairesmedicineAcupunctureHumansAmitriptylinemigraine030212 general & internal medicineadolescentsPractice Patterns Physicians'ChildFlunarizineRetrospective Studiestreatmentbusiness.industryAnti-Inflammatory Agents Non-SteroidalGeneral Medicineadolescents; children; migraine; primary headaches; tension-type headache; treatmentPerinatology and Child Healthmedicine.diseasetension-type headacheMigraineTolerabilityItalyPediatrics Perinatology and Child HealthCohortAnticonvulsantsFemaleprimary headachesNeurology (clinical)businessheadache030217 neurology & neurosurgeryPrimary headaches; Migraine; Tension-type; headache; Treatment; Children; Adolescentsmedicine.drug
researchProduct

Effects on executive functions of antiepileptic monotherapy in pediatric age.

2020

Abstract Objectives Cognitive abilities and executive functions in children and adolescents are important indicators of quality of life as well as academic and social achievements. Cognitive and executive functioning are often impaired in patients with epilepsy and can be exacerbated by seizures and antiseizure drugs. The aim of our observational retrospective study was to assess executive functioning in patients with pediatric epilepsy, currently taking a single antiseizure medication. Materials and methods Records of 172 children and adolescents aged between 6 and 18 years (mean age = 12 ± 3.4 years) with newly diagnosed epilepsy who had not yet commenced an antiepileptic treatment were i…

MalePediatricsmedicine.medical_specialtyLevetiracetamAdolescentAntiepileptic drugsOxcarbazepine03 medical and health sciencesBehavioral NeuroscienceEpilepsyExecutive Function0302 clinical medicinemedicineHumans030212 general & internal medicineOxcarbazepineChildChildrenRetrospective StudiesValproic AcidEpilepsybusiness.industrySeizure typesEpiTrack JuniorAge FactorsCarbamazepinemedicine.diseaseExecutive functionsTolerabilityCognitive functionsAntiepileptic drugs; Children; Cognitive functions; EpiTrack Junior; Executive function; TolerabilityCarbamazepineNeurologyTolerabilityQuality of LifeAnticonvulsantsFemaleCognitive functionNeurology (clinical)LevetiracetambusinessAntiepileptic drug030217 neurology & neurosurgerymedicine.drugEpilepsybehavior : EB
researchProduct

The safety and efficacy of add-on levetiracetam in elderly patients with focal epilepsy: A one-year observational study

2011

Abstract Purpose The long-term safety and efficacy of levetiracetam (LEV) was evaluated as add-on therapy in focal epilepsy patients ( n =491) aged at least 65 years who failed at least one monotherapy. Methods Patients ( n =491) with focal epilepsy treated with at least one antiepileptic drug in monotherapy with insufficient seizure control were included in this prospective open-label study. The recommended LEV dose range was 1000–3000mgperday. Follow-up visits were done approximately after 3, 6 and 12 months. Safety and efficacy was analysed based on all patients who received LEV (safety population, n =491) and all patients who were seen at all visits and completed the trial (per protocol…

MalePediatricsmedicine.medical_specialtyLevetiracetamEfficacyPopulationClinical NeurologyEpilepsyPharmacotherapyElderlySeizure controlmedicineHumanseducationAdverse effectAgedAged 80 and overeducation.field_of_studyEpilepsybusiness.industryGeneral Medicinemedicine.diseasePiracetamClinical trialTreatmentNeurologyAnesthesiaAnticonvulsantsDrug Therapy CombinationFemaleObservational studyEpilepsies PartialNeurology (clinical)LevetiracetamSafetybusinessmedicine.drugSeizure
researchProduct